Skip to content
WorldBrand.AI

HUTCHMED (formerly Hutchison China MediTech)

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2026

    Imported Cancer Drug Tazverik Withdrawn and Recalled Less Than a Year After Launch Due to Safety Risk

    Because of the risk of secondary hematologic malignancies, which may outweigh the benefits, the cancer drug Tazverik (tazemetostat), introduced by HUTCHMED, initiated market withdrawal, recall, and termination of related clinical trials in China in March 2026; the National Healthcare Security Administration removed it from online listing and from the commercial insurance innovative drug directory.

    Source